New business model to relaunch the BioPharma industry, from ADL

Traditionally, clinical diagnoses and treatments have focused on diseases and cures. For every ailment, one or several treatments were developed, which aimed to treat all patients diagnosed with the disease in case, with the individual patient not taking part in the decision process.

Although this “one size fits all” model has served humanity well, it is slowly showing its limitations. Arthur D Little’s latest viewpoint “The Curing Company” proposes a new business model using the available technologies to achieve the necessary transformation.

The rise of “personalized medicine,” emphasizing the customization of health care and patient centricity, has given way to the idea of the “Curing Company:” the company which looks after the entire two-way link between the patient and the treatment. As the individualized cure sits at the crossroad of technology, treatment and information, hardly any company possesses all of the necessary expertise to do the job. The major hurdle to be overcome is the vast scale of competencies required to be a true “closed loop” Curing Company.